COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00047190
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : June 4, 2013
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
Phase II trial to study the effectiveness of tipifarnib in treating patients who have myelofibrosis with myeloid metaplasia. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

Condition or disease Intervention/treatment Phase
Essential Thrombocythemia Polycythemia Vera Primary Myelofibrosis Drug: tipifarnib Other: laboratory biomarker analysis Phase 2

Detailed Description:


I. To evaluate the response rate in MMM patients treated with R115777. II. To evaluate the toxicity of R115777 in patients with MMM.


I. To evaluate the benefit of therapy with R115777 in alleviating disease-associated anemia in patients with MMM.

II. To evaluate the benefit of R115777 in reducing palpable splenomegaly in patients with MMM.

III. To evaluate the effect of R115777 on the hypercatabolic symptoms from MMM. IV. To evaluate the effect of R115777 on the pathologic increase in circulating myeloid progenitors in MMM patients through baseline measurement and measurement after the first cycle.

V. To correlate response/relapse with in vitro myeloid colony sensitivity to R115777 at the time of either response or relapse.

VI. To evaluate the effect of R115777 on bone marrow histologic features of MMM including osteosclerosis, reticulin fibrosis, and angiogenesis (through serial bone marrow microvessel density grading).

OUTLINE: This is a multicenter study.

Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months until disease progression and then every 6 months for up to 2 years.

PROJECTED ACCRUAL: A total of 18-35 patients will be accrued for this study within 15 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of R115777 in Myelofibrosis With Myeloid Metaplasia (MMM)
Study Start Date : August 2002
Actual Primary Completion Date : April 2007

Arm Intervention/treatment
Experimental: Arm I
Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Drug: tipifarnib
Given PO
Other Names:
  • R115777
  • Zarnestra

Other: laboratory biomarker analysis
Correlative studies

Primary Outcome Measures :
  1. Confirmed response defined as the objective status of complete response (CR) or partial response (PR) on 2 consecutive evaluations at least 4 weeks apart [ Time Frame: Up to 2 years ]
    Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Time from registration to death due to any cause, assessed up to 2 years ]
    Estimated using the method of Kaplan-Meier.

  2. Time to progression [ Time Frame: Time from registration to the time of progression, assessed up to 2 years ]
    Estimated using the method of Kaplan-Meier.

  3. Duration of response [ Time Frame: Date of complete response to the date progression is documented (if one has occurred) or to the date of last follow-up (for those patients who have not progressed), assessed up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histopathologic confirmation (on bone marrow trephine and aspirate) of myelofibrosis with myeloid metaplasia by a pathologist/hematologist at the registering institution; included in the diagnosis of MMM are AMM (agnogenic myeloid metaplasia), PPMM (post-polycythemic myeloid metaplasia), and PTMM (post-thrombocythemic myeloid metaplasia); the bone marrow should show the presence of reticulin fibrosis, and the peripheral blood smear should show the presence of leukoerythroblastosis and dacrocytosis
  • Bone marrow showing no evidence of other conditions associated with myelofibrosis, such as metastatic carcinoma, lymphoma, myelodysplasia, hairy cell leukemia, mast cell disease, acute leukemia (including M7 type), or acute myelofibrosis
  • Bone marrow chromosome analysis or peripheral blood or bone marrow Fluorescent In Situ Hybridization (FISH) showing absence of chromosomal translocation t(9:22); prior demonstration is sufficient for enrollment purposes
  • At least one of the following:

    • Anemia evidenced by hemoglobin < 10 g/dL
    • Palpable hepato-splenomegaly
  • ANC ≥ 750/mm^3
  • PLT ≥ 100,000/mm^3
  • Total bilirubin (direct if total elevated) ≤ UNL
  • Alkaline phosphatase =< 3 x UNL (unless felt to be secondary to disease)
  • AST ≤ 2.5 x UNL
  • Creatinine =< 1.5 x UNL
  • Ability to understand and the willingness to sign a written informed consent document
  • Willingness to follow the schedule for returning to the registering P2C institution (monthly) while receiving protocol treatment
  • ECOG performance status 0, 1, or 2

Exclusion Criteria:

  • Any of the following as this regimen may be harmful to a developing fetus or nursing child:

    • Pregnant women
    • Breastfeeding women
    • Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.)
    • NOTE: The effects of the agent(s) on the developing human fetus at the recommended therapeutic dose are unknown
  • Use of cytotoxic chemotherapy or other myelosuppressive agents within =< 2 weeks prior to study entry
  • Uncontrolled intercurrent illness or any co-morbid condition that would limit compliance with study requirements or with which the use of R115777 is felt to be potentially harmful; such conditions include, but are not limited to:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia, or
    • Psychiatric illness/social situations
  • Other concurrent therapy directed at the disease (including Thalidomide) or use of erythropoietin while enrolled in this study; such agents must be discontinued at the time of or prior to study entry
  • Known quinolone sensitivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00047190

Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Ruben Mesa Mayo Clinic
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00047190    
Other Study ID Numbers: NCI-2012-02804
N01CM17104 ( U.S. NIH Grant/Contract )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: June 4, 2013
Last Verified: June 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Polycythemia Vera
Primary Myelofibrosis
Thrombocythemia, Essential
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Bone Marrow Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Blood Platelet Disorders
Blood Coagulation Disorders
Hemorrhagic Disorders
Pathologic Processes
Antineoplastic Agents